Semaglutide Injector is named as an intervention in 3 current clinical trials in our Canada and Belgium registers. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Universitaire Ziekenhuizen KU Leuven (1). The most-studied condition is Glucose Intolerance After a Recent History of Gestational Diabetes.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
NCT06852391 · ClinicalTrials.gov ↗ · Obesity (Disorder)
|
Phase 4 | Recruiting | McMaster University | Canada |
|
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
NCT05569772 · ClinicalTrials.gov ↗ · Glucose Intolerance After a Recent History of Gestational Diabetes
|
Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | Belgium |
|
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
NCT06908694 · ClinicalTrials.gov ↗ · Prostate Cancer
|
Phase 4 | Active, closed | Hamilton Health Sciences Corporation | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Hamilton Health Sciences Corporation | 1 |
| McMaster University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 2 | 1 |
| Clinical trials in Belgium | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Canada and Belgium registers name Semaglutide Injector as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Canada and 1 with sites in Belgium. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Universitaire Ziekenhuizen KU Leuven (1), Hamilton Health Sciences Corporation (1) and McMaster University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Semaglutide Injector works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Semaglutide Injector works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Semaglutide Injector (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.